LESS TOXIC NANOPARTICLES OF PLATINUM BASED ANTI-CANCER DRUG

Objectives: The objective of this research was dose reduction and toxicity reduction. Dose reduction: various anti-cancer drugs are very costly, and their high dose increases cost. If bioavailability is enhanced, the dose shall be reduced thereby; the cost will also decrease. Dose reduction will also reduce toxicity, and the preparation will become more tolerable. Method: In this study, the nanoparticles were developed by using a modified method with the drug cisplatin, which was later evaluated for stability, toxicity, and therapeutic efficacy using various in-vitro and in-vivo techniques like SRB assay. Results: The resulting dosage form found to be more affected and less toxic than the marketed preparation of drug cisplatin, which is i.v. injection. As cisplatin is a platinum compound and has the biggest drawback of the toxic side effects, which is making the chemotherapy less acceptable but with the preparation of nanoparticles side effects were minimized without harming the therapeutic efficacy. Anti-cancer agents have several adverse side effects and high levels of toxicity, e.g., Hair loss due to the effects on hair follicles, anemia, immune system impairment, and clotting problems, reduction in the number of red cells, white cells, and platelets. Conclusion: The nanoparticles were prepared using a new generation polymer, namely EUDRAGIT. The method was self-modified for the preparation of these nanoparticles. Process optimization and validation were done before the final nanoparticles were obtained. The nanoparticles obtained were smooth and almost round as elicited by SEM and stable more than a year as concluded from stabilities studies.